Bausch Health Companies Inc BHC.TO is expected to show a rise in quarterly revenue when it reports results on February 19 for the period ending December 31 2024
The Laval Quebec-based company is expected to report a 4.3% increase in revenue to $2.512 billion from $2.41 billion a year ago, according to the mean estimate from 6 analysts, based on LSEG data.
LSEG's mean analyst estimate for Bausch Health Companies Inc is for earnings of $1.13 per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 5 "hold" and 1 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Bausch Health Companies Inc is $8.50, above its last closing price of $6.16.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | 1.00 | 1.02 | 1.13 | Beat | 10.3 |
Jun. 30 2024 | 0.87 | 0.88 | 0.89 | Beat | 1.6 |
Mar. 31 2024 | 0.73 | 0.72 | 0.60 | Missed | -16.4 |
Dec. 31 2023 | 1.03 | 1.02 | 1.15 | Beat | 12.5 |
Sep. 30 2023 | 0.92 | 0.92 | 1.02 | Beat | 11.3 |
Jun. 30 2023 | 0.78 | 0.78 | 0.82 | Beat | 5.6 |
Mar. 31 2023 | 0.73 | 0.72 | 0.52 | Missed | -27.6 |
Dec. 31 2022 | 0.92 | 0.91 | 1.03 | Beat | 13.7 |
This summary was machine generated February 17 at 21:54 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)